Secondary Logo

Institutional members access full text with Ovid®

Pancreatic Ductal Adenocarcinoma With High Radiotracer Uptake in 68Ga–Prostate-Specific Membrane Antigen PET/CT

Sahbai, Samine, MD*; Rieping, Petra, MD; Pfannenberg, Christina, MD; la Fougére, Christian, MD*; Reimold, Matthias, MD*

doi: 10.1097/RLU.0000000000001767
Interesting Images

Prostate-specific membrane antigen imaging with PET/CT is increasingly used in prostate cancer and was shown to have a high diagnostic performance. We report a clinical case of a 67-year-old man with previous history of operated prostate cancer and increasing prostate-specific antigen blood level. 68Ga-HBED-CC prostate-specific membrane antigen PET/CT imaging was indicated for the assessment of local recurrence and lymph node metastases of prostate cancer. In addition, a soft tissue mass in the body of the pancreas with high radiotracer uptake was detected. Histopathology confirmed a pancreatic ductal adenocarcinoma.

From the *Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital of Tübingen, Tübingen; †Institute of Pathology, Sindelfingen-Böblingen Clinical Centre, Böblingen; and ‡Department of Diagnostic and Interventional Radiology, University Hospital of Tübingen, Tübingen, Germany.

Received for publication April 30, 2017; revision accepted June 9, 2017.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent was obtained from the patient for the use of anonymized imaging, clinical, and histopathologic data.

Statement of authorship and contribution of authors: S.S. and M.R. devised the rationale and designed the case report; S.S. wrote the original abstract, collected the clinical data, and took the images; C.F., C.P., and M.R. supervised the article; S.S. and M.R. analyzed and interpreted the data; S.S., C.L.F., M.R., and C.P. participated in revision; P.R. interpreted the histopathologic results and immunohistochemistry. All authors have read and approved the final version of the present article.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Samine Sahbai, MD, Otfried-Müller-Straße 14, 72076 Tübingen, Germany. E-mail:

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.